Search
Search Results
-
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
BackgroundFibroblast growth factor-23 (FGF23) has been associated to left ventricular (LV) hypertrophy and heart failure (HF) severity. We aimed to...
-
Predictors of mortality in heart failure patients with reduced or mildly reduced Ejection Fraction: The CASABLANCA HF Study
BackgroundHeart failure (HF) poses a significant public health challenge throughout the world and Morocco. Our objective was to delineate the...
-
Stroke and Recent Myocardial Infarction, Reduced Left Ventricular Ejection Fraction, Left Ventricular Thrombus, and Wall Motion Abnormalities
Purpose of ReviewTo review the evidence regarding stroke and recent myocardial infarction (MI), reduced left ventricular ejection fraction, left...
-
Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction
AimsAs there is limited evidence regarding the prognostic impact of prior left ventricular ejection fraction (LVEF) in patients with heart failure...
-
Revascularization in Ischemic Heart Failure with Reduced Left Ventricular Ejection Fraction
Purpose of ReviewCoronary artery disease (CAD) is estimated to account for over 60% of heart failure (HF) patients and is associated with worse...
-
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction?
Heart failure (HF) with preserved ejection fraction (HFpEF) causes a progressive limitation of functional capacity, poor quality of life (QoL) and...
-
Low-flow in aortic valve stenosis patients with reduced ejection fraction does not depend on left ventricular function
BackgroundPatients with severe aortic stenosis (AS) and reduced left ventricular ejection fraction (LVEF) can be distinguished into high- (HG) and...
-
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Guideline-directed medical therapy (GDMT) is the cornerstone of pharmacological therapy for patients with heart failure with reduced ejection...
-
Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction
BackgroundQuadruple therapy (renin angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium/glucose...
-
Timing of prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced/mildly reduced ejection fraction: a retrospective analysis
Although angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) play critical roles in the treatment of heart...
-
Diabetes mellitus in patients with heart failure and reduced ejection fraction: a post hoc analysis from the WARCEF trial
Patients with heart failure with reduced ejection fraction (HFrEF) and diabetes mellitus (DM) have an increased risk of adverse events, including...
-
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
BackgroundRecent data suggest different causes of renal dysfunction between heart failure with reduced (HFrEF) versus preserved ejection fraction...
-
New onset heart failure with reduced ejection fraction management: single center, real-life Tunisian experience
BackgroundHeart failure (HF) is a serious and frequent pathology. It represents a major public health problem. We have few data about this pathology...
-
Effect of dapagliflozin on ventricular repolarization in patients with heart failure with reduced ejection fraction
Whether sodium–glucose cotransporter-2 inhibitors (SGLT2is) reduce ventricular arrhythmias and sudden cardiac death is controversial. Ventricular...
-
Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients
Heart failure with reduced ejection fraction (HFrEF) represents an emerging epidemic, particularly affecting frail, older, and multimorbid patients....
-
Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction
Not much is known about the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on echocardiographic parameters of left ventricular (LV)...
-
Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
PurposeThe DELIVER trial demonstrated the efficacy of dapagliflozin in reducing primary endpoint (cardiovascular (CV) mortality or worsening heart...
-
Echocardiographic predictors of outcome in severe aortic stenosis patients with preserved or reduced ejection fraction
AimsTranscatheter aortic valve implantation (TAVI) has emerged as the treatment of choice for many patients with severe symptomatic aortic stenosis....
-
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
AimsSacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed...
-
Increased epicardial adipose tissue is associated with left atrial mechanical dysfunction in patients with heart failure with mildly reduced and preserved ejection fraction
IntroductionHeart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF) is often accompanied by atrial dysfunction. It has...
